Marketing authorisation
Colin Kerr
Published: Monday, March 1, 2021
Aerie Pharmaceuticals has announced that the European Commission (EC) has granted a marketing authorisation for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. The marketing authorisation application for Roclanda was accepted for review by the European Medicines Agency in January 2020.
www.aeriepharma.com